Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX)

Historical Holders from Q1 2016 to Q3 2025

Symbol
SNDX on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
86,559,040
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
101,127,447
Holdings value
$1,555,904,491
% of all portfolios
0.01%
Number of holders
224
Number of buys
121
Number of sells
-98
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Kynam Capital Management, LP 9.98% $113,571,600 8,520,000 Kynam Capital Management, LP 31 Dec 2024
BlackRock, Inc. 7.8% $89,898,173 6,744,049 BlackRock, Inc. 31 Mar 2025
GOLDMAN SACHS GROUP INC 6.5% +26% $51,576,091 +$9,897,509 5,581,828 +24% THE GOLDMAN SACHS GROUP, INC. 30 Jun 2025
Point72 Asset Management, L.P. 5% +77% $44,621,185 +$20,827,520 4,327,952 +88% Point72 Asset Management, L.P. 15 Aug 2025
MORGAN STANLEY 2.4% -65% $27,193,373 -$44,284,339 2,040,013 -62% Morgan Stanley 31 Mar 2025
WELLINGTON MANAGEMENT GROUP LLP 0% $475,628 35,681 Wellington Management Group LLP 28 Feb 2025

Institutional Holders of Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX)

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 101,127,447 $1,555,904,491 +$19,108,722 $15.38 224
2025 Q2 101,743,087 $952,765,629 -$3,412,831 $9.36 214
2025 Q1 100,841,762 $1,238,937,353 +$32,280,128 $12.28 215
2024 Q4 98,036,463 $1,295,985,057 +$87,204,107 $13.22 214
2024 Q3 88,967,889 $1,713,503,490 +$22,962,287 $19.25 208
2024 Q2 87,359,094 $1,793,463,324 -$71,085,162 $20.53 195
2024 Q1 90,291,619 $2,148,803,982 +$45,990,918 $23.8 188
2023 Q4 88,660,945 $1,915,962,261 +$405,830,138 $21.61 176
2023 Q3 71,017,590 $1,031,468,287 -$1,236,482 $14.52 174
2023 Q2 70,660,286 $1,478,899,897 -$48,383,346 $20.93 165
2023 Q1 72,989,203 $1,541,067,785 +$23,662,697 $21.12 161
2022 Q4 71,468,832 $1,818,847,118 +$262,720,878 $25.45 159
2022 Q3 59,986,014 $1,441,473,166 +$97,845,580 $24.03 136
2022 Q2 55,225,664 $1,062,543,225 +$21,478,133 $19.24 116
2022 Q1 54,572,890 $948,388,792 -$36,428,045 $17.38 136
2021 Q4 52,428,774 $1,146,955,026 +$54,297,905 $21.89 129
2021 Q3 49,078,197 $938,007,416 -$20,732,602 $19.11 121
2021 Q2 50,204,902 $861,938,071 +$12,311,173 $17.17 113
2021 Q1 48,482,656 $1,083,969,550 +$46,478,159 $22.36 130
2020 Q4 46,493,166 $1,034,139,433 +$269,937,051 $22.24 140
2020 Q3 34,234,622 $505,296,990 +$23,535,263 $14.76 98
2020 Q2 32,648,161 $483,839,331 +$177,178,450 $14.82 96
2020 Q1 20,764,120 $227,777,510 +$45,430,574 $10.97 81
2019 Q4 16,674,566 $146,400,674 -$3,736,906 $8.78 71
2019 Q3 17,141,763 $128,044,931 -$811,927 $7.47 72
2019 Q2 17,174,052 $159,885,671 +$3,968,740 $9.31 71
2019 Q1 16,955,330 $89,016,913 +$8,086,878 $5.25 66
2018 Q4 15,460,307 $68,794,733 -$2,725,288 $4.45 73
2018 Q3 15,338,464 $123,912,664 +$3,406,829 $8.08 73
2018 Q2 15,085,582 $105,898,739 -$23,251,843 $7.02 83
2018 Q1 17,173,123 $244,377,218 +$5,182,148 $14.23 72
2017 Q4 17,172,317 $150,421,862 +$15,929,302 $8.76 77
2017 Q3 15,034,508 $175,968,675 -$8,293,783 $11.7 67
2017 Q2 15,705,504 $219,397,678 +$56,766,148 $13.97 63
2017 Q1 11,652,824 $159,872,123 +$30,204,104 $13.72 62
2016 Q4 11,123,178 $79,752,466 -$4,867,203 $7.17 55
2016 Q3 11,599,012 $175,841,071 +$19,928,095 $15.16 45
2016 Q2 10,263,556 $101,043,565 +$10,817,957 $9.85 46
2016 Q1 9,443,951 $125,631,000 +$125,631,000 $13.32 27